CLSD logo

Clearside Biomedical (CLSD) Cash From Operations

Annual CFO

-$18.14 M
-$4.77 M-35.69%

December 31, 2023

Summary

Performance

1-Year Change

-35.69%

3-Year Change

-38.22%

5-Year Change

+77.1%

15-Year Change

+64.5%

CLSD Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

49.06%
CLSD annual cash flow from operations is higher than 49.06% of companies in Healthcare sector

High & Low

All-time High

-$6.84 M

3-Year Low

-$18.14 M
CLSD annual cash flow from operations is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
CLSD previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 12, 2025
CLSD next annual earnings announcement is scheduled for Mar 12, 2025

OtherCLSDcash flowmetrics:

Annual CFI

-$1.78 M
CLSD annual cash flow from investing activities is -$1.78 million

Annual CFF

$414.00 K
CLSD annual cash flow from financing activities is $414.00 thousand

Annual FCF

-$19.91 M
CLSD annual free cash flow is -$19.91 million

Annual CAPEX

$1.78 M
CLSD annual capital expenditures is $1.78 million

Quarterly CFO

-$5.91 M
-$233.00 K-4.10%

September 30, 2024

Summary

Performance

3-Month Change

-4.1%

1-Year Change

+2.67%

3-Year Change

+2.67%

5-Year Change

+2.67%

CLSD Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

42.14%
CLSD quarterly cash flow from operations is higher than 42.14% of companies in Healthcare sector

High & Low

All-time High

$5.05 M
CLSD quarterly cash flow from operations is currently -217.00% below its historical high of $5.05 million

3-Year Low

-$7.85 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
CLSD previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 12, 2025
CLSD next earnings announcement is scheduled for Mar 12, 2025

OtherCLSDcash flowmetrics:

Quarterly CFI

$1.55 M
CLSD quarterly cash flow from investing activities is $1.55 million

Quarterly CFF

$14.00 K
CLSD quarterly cash flow from financing activities is $14.00 thousand

Quarterly FCF

-$5.97 M
CLSD quarterly free cash flow is -$5.97 million

Quarterly CAPEX

$53.00 K
CLSD quarterly capital expenditures is $53.00 thousand

TTM CFO

-$18.95 M
+$162.00 K+0.85%

September 30, 2024

Summary

Performance

3-Month Change

+0.85%

1-Year Change

+21.82%

3-Year Change

+21.82%

5-Year Change

+21.82%

CLSD TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

46.27%
CLSD TTM cash flow from operations is higher than 46.27% of companies in Healthcare sector

High & Low

All-time High

$204.00 K
CLSD TTM cash flow from operations is currently -9388.73% below its historical high of $204.00 thousand

3-Year Low

-$24.45 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
CLSD previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 12, 2025
CLSD next earnings announcement is scheduled for Mar 12, 2025

OtherCLSDcash flowmetrics:

TTM CFI

-$10.06 M
CLSD TTM cash flow from investing activities is -$10.06 million

TTM CFF

$14.10 M
CLSD TTM cash flow from financing activities is $14.10 million

TTM FCF

-$19.60 M
CLSD TTM free cash flow is -$19.60 million

TTM CAPEX

$653.00 K
CLSD TTM capital expenditures is $653.00 thousand

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

CLSD Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-35.7%+2.7%+21.8%
3 y3 years-38.2%+2.7%+21.8%
5 y5 years+77.1%+2.7%+21.8%

CLSD Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-69.0%at low-217.0%+24.7%-9388.7%+22.5%
5 y5-year-69.0%+33.0%-217.0%+24.7%-9388.7%+30.0%
alltimeall time-165.2%+77.1%-217.0%+75.6%-9388.7%+76.1%

Clearside Biomedical Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$5.91 M(+4.1%)
-$18.95 M(-0.8%)
Jun 2024
-
-$5.68 M(-27.7%)
-$19.11 M(+1.8%)
Mar 2024
-
-$7.85 M(-1686.1%)
-$18.77 M(+3.5%)
Dec 2023
-$18.14 M(+35.7%)
$495.00 K(-108.1%)
-$18.14 M(-25.2%)
Sep 2023
-
-$6.08 M(+13.8%)
-$24.24 M(-0.5%)
Jun 2023
-
-$5.34 M(-26.0%)
-$24.35 M(-0.4%)
Mar 2023
-
-$7.22 M(+28.7%)
-$24.45 M(+83.0%)
Dec 2022
-$13.37 M(+24.5%)
-$5.61 M(-9.4%)
-$13.37 M(+394.3%)
Sep 2022
-
-$6.19 M(+13.7%)
-$2.70 M(-1425.5%)
Jun 2022
-
-$5.44 M(-240.6%)
$204.00 K(-115.7%)
Mar 2022
-
$3.87 M(-23.4%)
-$1.30 M(-87.9%)
Dec 2021
-$10.73 M(-18.2%)
$5.05 M(-254.2%)
-$10.73 M(-46.9%)
Sep 2021
-
-$3.28 M(-52.8%)
-$20.22 M(+3.1%)
Jun 2021
-
-$6.95 M(+25.0%)
-$19.61 M(+23.5%)
Mar 2021
-
-$5.56 M(+25.3%)
-$15.88 M(+21.0%)
Dec 2020
-$13.12 M(-51.5%)
-$4.44 M(+66.7%)
-$13.12 M(+87.6%)
Sep 2020
-
-$2.66 M(-17.4%)
-$7.00 M(-32.6%)
Jun 2020
-
-$3.22 M(+14.9%)
-$10.38 M(-39.7%)
Mar 2020
-
-$2.80 M(-266.0%)
-$17.22 M(-36.4%)
Dec 2019
-$27.07 M
$1.69 M(-127.9%)
-$27.07 M(-48.9%)
DateAnnualQuarterlyTTM
Sep 2019
-
-$6.05 M(-39.9%)
-$53.02 M(-20.5%)
Jun 2019
-
-$10.06 M(-20.5%)
-$66.69 M(-12.5%)
Mar 2019
-
-$12.65 M(-47.8%)
-$76.20 M(-3.8%)
Dec 2018
-$79.20 M(+55.0%)
-$24.26 M(+23.0%)
-$79.20 M(+13.1%)
Sep 2018
-
-$19.72 M(+0.8%)
-$70.03 M(+9.8%)
Jun 2018
-
-$19.57 M(+25.0%)
-$63.78 M(+14.4%)
Mar 2018
-
-$15.65 M(+3.7%)
-$55.76 M(+9.2%)
Dec 2017
-$51.08 M(+124.9%)
-$15.09 M(+12.1%)
-$51.08 M(+20.3%)
Sep 2017
-
-$13.46 M(+16.5%)
-$42.45 M(+20.0%)
Jun 2017
-
-$11.55 M(+5.2%)
-$35.36 M(+20.7%)
Mar 2017
-
-$10.98 M(+70.0%)
-$29.29 M(+29.0%)
Dec 2016
-$22.71 M(+63.4%)
-$6.46 M(+1.3%)
-$22.71 M(+13.1%)
Sep 2016
-
-$6.37 M(+16.3%)
-$20.08 M(+19.1%)
Jun 2016
-
-$5.48 M(+24.7%)
-$16.86 M(+15.9%)
Mar 2016
-
-$4.40 M(+14.8%)
-$14.55 M(+4.7%)
Dec 2015
-$13.90 M(+52.4%)
-$3.83 M(+21.5%)
-$13.90 M(+38.0%)
Sep 2015
-
-$3.15 M(-0.7%)
-$10.07 M(+45.5%)
Jun 2015
-
-$3.17 M(-15.3%)
-$6.92 M(+84.7%)
Mar 2015
-
-$3.75 M
-$3.75 M
Dec 2014
-$9.12 M(+33.4%)
-
-
Dec 2013
-$6.84 M
-
-

FAQ

  • What is Clearside Biomedical annual cash flow from operations?
  • What is the all time high annual CFO for Clearside Biomedical?
  • What is Clearside Biomedical annual CFO year-on-year change?
  • What is Clearside Biomedical quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Clearside Biomedical?
  • What is Clearside Biomedical quarterly CFO year-on-year change?
  • What is Clearside Biomedical TTM cash flow from operations?
  • What is the all time high TTM CFO for Clearside Biomedical?
  • What is Clearside Biomedical TTM CFO year-on-year change?

What is Clearside Biomedical annual cash flow from operations?

The current annual CFO of CLSD is -$18.14 M

What is the all time high annual CFO for Clearside Biomedical?

Clearside Biomedical all-time high annual cash flow from operations is -$6.84 M

What is Clearside Biomedical annual CFO year-on-year change?

Over the past year, CLSD annual cash flow from operations has changed by -$4.77 M (-35.69%)

What is Clearside Biomedical quarterly cash flow from operations?

The current quarterly CFO of CLSD is -$5.91 M

What is the all time high quarterly CFO for Clearside Biomedical?

Clearside Biomedical all-time high quarterly cash flow from operations is $5.05 M

What is Clearside Biomedical quarterly CFO year-on-year change?

Over the past year, CLSD quarterly cash flow from operations has changed by +$162.00 K (+2.67%)

What is Clearside Biomedical TTM cash flow from operations?

The current TTM CFO of CLSD is -$18.95 M

What is the all time high TTM CFO for Clearside Biomedical?

Clearside Biomedical all-time high TTM cash flow from operations is $204.00 K

What is Clearside Biomedical TTM CFO year-on-year change?

Over the past year, CLSD TTM cash flow from operations has changed by +$5.29 M (+21.82%)